# Onward Therapeutics funding rounds and investors

As of 19 Nov 2026, Onward Therapeutics has raised $28M across 1 verified round on record (amounts in other currencies converted to USD); latest: NT$900 million (approximately US$28 million) Series B, announced 17 Nov 2026.

A clinical-stage drug development company focused on overcoming cancer drug resistance

Website: http://www.onward-therapeutics.com  
Headquarters: Taipei, Taiwan  
Page: https://fireround.dev/companies/onward-therapeutics

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-11-17 | Series B | NT$900 million (approximately US$28 million) | not stated | Beiley Biofund, CDIB Capital Healthcare Ventures, Everbright Biofund, Grand Fortune Venture Capital, Hercules Bioventure Partners, Hong Kong Chlitina International, MitoBitTech Venture, Test Rite International, Top Taiwan Venture Capital | [prnewswire.com](https://www.prnewswire.com/news-releases/onward-therapeutics-closes-nt900-million-approximately-us28-million-series-b-financing-to-advance-clinical-stage-oncology-pipeline-302942490.html), [biospace.com](https://www.biospace.com/press-releases/onward-therapeutics-closes-nt-900-million-approximately-us-28-million-series-b-financing-to-advance-clinical-stage-oncology-pipeline), [bebeez.eu](https://bebeez.eu/2026/11/18/onward-therapeutics-closes-nt900-million-approximately-us28-million-series-b-financing-to-advance-clinical-stage-oncology-pipeline) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.
